MedTrace Logo

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

NCT03327727 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-02-27

No results posted yet for this study

Summary

The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.

Conditions

  • Invasive Aspergillosis
  • Invasive Pulmonary Aspergillosis

Interventions

DRUG

Investigational Agent: VL-2397

VL-2397

DRUG

Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B

Voriconazole, Isavuconazole, or Liposomal amphotericin B

Sponsors & Collaborators

  • Vical

    lead INDUSTRY

Principal Investigators

  • Mammen P Mammen, MD, FIDSA · Vical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-20
Primary Completion
2019-01-14
Completion
2019-01-14
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • France
  • Germany
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03327727 on ClinicalTrials.gov